Monday, December 23

Tag: procedures

Congress Moves Forward on Roughly $900 Billion Defense Bill
7Dec By adminNo Comments
World

Congress Moves Forward on Roughly $900 Billion Defense Bill

WASHINGTON—House and Senate lawmakers agreed to scrap the most contentious pieces of a nearly $900 billion defense and national security policy bill, such as restrictions on abortion and transgender care for service members, clearing the way for its passage by the end of the year.Lawmakers who serve on both chambers’ Armed Services committees on Wednesday night released compromise text for the annual National Defense Authorization Act. This year’s NDAA, which lays out top policy priorities for the Pentagon, calls for a 5.2% pay raise for service members and military training assistance to Taiwan to help the island defend itself against a possible invasion by China. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Tuberville’s Hard Beltway Education – WSJ
6Dec By adminNo Comments
Health

Tuberville’s Hard Beltway Education – WSJ

The Senate on Tuesday approved 425 U.S. military promotions, which usually wouldn’t attract much attention. But Republican Tommy Tuberville had for months held these officers as hostages in a fight with the Biden Pentagon over abortion. Give the Alabama Senator credit for relenting. Sen. Tuberville announced he’d release most of his holds, with the exception of a handful of four-star officers. Senate Democrats had been floating a procedural resolution to duck Sen. Tuberville’s blockade, a risky precedent that could cramp every Senator’s prerogatives to review nominees. That was an institutional outcome worth avoiding.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Tommy Tuberville Backs Down in Fight Over Military Promotions
5Dec By adminNo Comments
World

Tommy Tuberville Backs Down in Fight Over Military Promotions

WASHINGTON—Alabama Sen. Tommy Tuberville ended his monthslong hold on nearly all military promotions, saying he would allow hundreds of officers to move forward, while still demanding individual votes for about a dozen four-star generals and admirals. “I’m not going to hold the promotions of these people any longer. We just released them, everybody,” Tuberville told reporters Tuesday. “I think about 440 of them, everybody but 10 or 11, four stars.”Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Using Keratin Treatments or Hair-Straightening Creams? Research Suggests Potential Cancer Risk.
4Dec By adminNo Comments
World

Using Keratin Treatments or Hair-Straightening Creams? Research Suggests Potential Cancer Risk.

Millions of women are using hair-straightening treatments and products that might be harmful to their health.More research is linking chemicals in these products to an increased risk of uterine, ovarian and breast cancer. Studies also suggest that frequent use of such products can negatively affect puberty and pregnancy. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Gene Editing Will Change Medicine—and Maybe Health Investing Too
24Nov By adminNo Comments
Money

Gene Editing Will Change Medicine—and Maybe Health Investing Too

It usually takes time for scientific discoveries in the lab to make their way to the market.The groundbreaking gene-editing technology known as Crispr, which acts like a molecular pair of scissors that can be used to cut and modify a DNA sequence, has moved rather quickly from the pages of scientific journals to the medical setting. Earlier this month, about three years after Jennifer Doudna and Emmanuelle Charpentier won the Nobel Prize in Chemistry for describing how bacteria’s immune system could be used as a tool to edit genes, regulators in the U.K. approved the first Crispr-based treatment for sickle cell disease and beta-thalassemia patients. The treatment, from Vertex Pharmaceuticals and Crispr Therapeutics, could be approved by the U.S. Food and Drug Administration early next mo...
Read More
The Covid Vaccine Windfall Turns for Pfizer and Moderna
19Nov By adminNo Comments
World

The Covid Vaccine Windfall Turns for Pfizer and Moderna

Updated Nov. 19, 2023 3:03 pm ETThe U.S. was in a fit of Covid panic during Thanksgiving week two years ago. The Omicron variant had emerged like a creature from the Black Lagoon. Public-health officials indicated we’d need another updated booster. Share prices in Pfizer and Moderna surged. By month’s end, Pfizer’s stock-market value had surpassed $300 billion, up 50% from the start of the pandemic. Moderna’s shares had soared by more than 1,000% over the same period. In 2022 Pfizer became the first pharmaceutical company to book more than $100 billion in annual sales owing to government purchases of its vaccines and antiviral pill.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Conservative Donors Failed to Show Up in the 2023 Elections
19Nov By adminNo Comments
Business

Conservative Donors Failed to Show Up in the 2023 Elections

Once critics of the supposedly malign influence of money in politics, the progressive left proved to be big spenders in November’s elections. In four key state races—for Kentucky’s governor, Virginia’s General Assembly, Pennsylvania’s Supreme Court and Ohio’s abortion referendum—left-wing advocacy groups dropped at least $135 million on campaign ads, outspending conservative groups by $42 million.A few years ago, left-leaning organizations and media outlets warned that conservatives had come to “dominate” state politics and policy. They pointed to Republican victories in state elections and significant policy achievements like the Wisconsin collective-bargaining reform known as Act 10. Those of us working in the trenches on these issues knew better. Government unions and progressive speci...
Read More
Bayer Pulling Lymphoma Drug Aliqopa From U.S.
13Nov By adminNo Comments
World

Bayer Pulling Lymphoma Drug Aliqopa From U.S.

Nov. 13, 2023 10:35 am ETGerman drugs-to-crops giant Bayer is pulling Aliqopa from the U.S. after a confirmatory trial of the lymphoma drug missed its primary endpoint.Bayer on Monday said it will work with the U.S. Food and Drug Administration on a voluntary withdrawal of Aliqopa, which won accelerated approval from the agency in 2017 for adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More